Haemonetics completes $255M OpSens acquisition

Haemonetics (NYSE: HAE) + announced today that it completed its previously announced acquisition of cardiology-focused medical device company OpSens.

Boston-based Haemonetics first announced plans to buy OpSens for more than $250 million in October. Upon completion of the deal, the company acquired all outstanding shares at a fully diluted equity value of about $255 million. As a result, OpSens common shares ceased trading in the public market and will be delisted from the Toronto Stock Exchange.

OpSens offers optical technology for use in interventional cardiology. Core products include the SavvyWire, a sensor-guided, 3-in-1 guidewire for transcatheter aortic valve replacement (TAVR) procedures. SavvyWire acts as a pacing and pressure monitoring wire, advancing procedure workflow and enabling shorter hospital stays.

The company’s OptoWire pressure guidewire aims to improve clinical outcomes by measuring F…

Read more
  • 0

Haemonetics to acquire OpSens for more than $250M, expanding cardiology device portfolio

Haemonetics (NYSE: HAE) + today announced a definitive agreement to acquire cardiology-focused technology developer OpSens.

Boston-based Haemonetics will acquire all outstanding shares of Opsens for CAD $2.90 in an all-cash transaction that will have a fully diluted equity value of approximately $253 million USD. The transaction is expected to close by the end of January 2024.

Opsens develops optical technology for use in interventional cardiology. Its products include the SavvyWire and OptoWire.

SavvyWire is a sensor-guided 3-in-1 guide wire for TAVR procedures that acts as a pacing and pressure monitoring wire that advances the workflow of the procedure for shorter hospital stays. OptoWire is a pressure guide wire that aims to improve clinical outcomes by accurately and consistently measuring fractional flow reserve (FFR) and diastolic pressure ratio to help clinicians in the diagnosis and treatment of coronary …
Read more
  • 0

Haemonetics brings vascular closure device to Europe

The Vascade MVP vascular closure device. [Image from Haemonetics]Haemonetics (NYSE:HAE) today announced the first patients treated with its Vascade MVP venous vascular closure system in Germany.

Boston-based Haemonetics said this marks the first use of the Vascade portfolio — widely used in the U.S. — in a European country.

The company designed Vascade for small-bore femoral arterial and venous closure. Its general uses include interventional cardiology and peripheral vascular procedures. Haemonetics developed Vascade MVP for mid-bore multi-access femoral venous closure, generally used in electrophysiology procedures.

Both closure devices hold CE mark approval in Europe. They cover patients who have undergone catheter-based procedures with single or multiple access sites in one or both limbs and include proprietary collapsible disc technology and a resorbable collagen patch to achieve hemostasis.

Haemonetics says its Vascade and Vascade MVP systems c…

Read more
  • 0

FDA clears enhancements to plasma collection tech from Haemonetics

Haemonetics (NYSE:HAE) announced that the FDA cleared advancements to its NexSys PCS plasma collection system.

Enhancements include a new plasma collection bowl and new Express Plus technology, according to a news release. The bowl features a patented design to optimize performance and Express Plus reduces procedure time.

Boston-based Haemonetics designed NexSys PCS as a completely integrated system for streamlining plasma collection. It improves yield, productivity, safety, quality, compliance and donor satisfaction. The latest advancements should produce an average procedure time of between 33 and 38 minutes, the company said. It should help customers achieve new levels of plasma center efficiency and lower costs to collect.

Haemonetics says NexSys PCS with NexLynk DMS donor management software already delivers a 16-minute reduction in donor door-to-door time. With Persona technology, it delivers between 9% and 12% additional plasma yield by personaliz…

Read more
  • 0

FDA clears Haemonetics next-gen autotransfusion system software

The Cell Saver Elite+ system. [Image from Haemonetics]Haemonetics (NYSE:HAE) announced today that it received FDA 510(k) clearance for next-generation software for the Cell Saver Elite+ autotransfusion system.

Boston-based Haemonetics began a full market release for the software update, named Intelligent Control. It designed the software to offer key enhancements to simplify operations, support efficiency and improve user experience.

Cell Saver Elite+ allows hospitals to recover a patient’s blood in surgical procedures. These procedures have the potential for medium to high blood loss, Haemonetics said in a news release. It helps to avoid unnecessary allogeneic transfusions while reducing related costs.

Procedures with the potential for high blood loss include cardiac, orthopedic, trauma, transplant, vascular and OBGYN surgeries. Haemonetics designed the system to recover blood, wash it and deliver it to a product bag.

According to Haemonetics,…

Read more
  • 0

Medtech jobs: The world’s largest medical device companies are hiring

Medical device companies are trying to fill thousand of medtech jobs. [Photo by ijeab – stock.adobe.com]

The world’s largest medical device companies are still hiring for medtech jobs despite layoffs in tech and other industries.

Medtech developers — and medtech jobs — are resilient, with the industry’s COVID-19 pandemic performance only bolstering its recession-proof reputation.

That’s not to say there haven’t been job cuts in medtech, led by thousands of layoffs at Philips as it struggles with a massive recall of deadly respiratory devices. But most medical device manufacturers are still hiring, and in some cases they can’t attract enough candidates to fill every vacancy in a tight labor market.

Stryker, for example, grew to approximately 51,000 employees as of the end of 2022, increasing its headcount by nearly 11 percent last year. Boston Scientific reported nearl…

Read more
  • 0

The biggest medtech stock gainers, losers in 2022

(From Ishant Mishra on Unsplash) In another roller coaster year for medtech, these are the companies that saw their stock rise and fall the most drastically.

The MassDevice MedTech 100 Index, which includes stocks of the world’s largest medical device companies, reflects the performance of many in the medtech space.

In a tough year for a lot of businesses, the Index wasn’t immune to struggles. Overall, it dropped 27.3% from this time last year. That compares to a 19.7% drop for the S&P 500 and an 8.9% dip for the Dow Jones Industrial Average.

Some businesses, though, powered through the supply chain- and inflation-related woes to see their stock rise from this time last year. Others weren’t so lucky. Here are some of the biggest gainers and losers — selected from the MedTech 100 Index — of 2022.

Biggest gainers BD — $245.27 to $254.97 — Up 4% 

While BD (NYSE:BDX) didn’t have the most significant growth, its stock remains in a …

Read more
  • 0

Haemonetics names Roy Galvin president of global plasma and blood center

Haemonetics (NYSE:HAE) announced today that it appointed Roy Galvin as president of its global plasma and blood center.

Galvin’s position becomes effective Oct. 10, 2022. He will report to Haemonetics President and CEO Chris Simon.

His responsibilities in the role include driving growth objectives and advancing the company’s leadership positions and innovation, according to a news release. He will oversee the delivery of collectors’ critical needs while supporting global demand for plasma-derived therapies.

Galvin’s role also includes the development of strategies to leverage Haemonetics’ global footprint. He will help to expand in the non-commercial plasma market through blood component collection.

“Haemonetics has long been the established leader in the plasma and blood collection markets for solutions that make a meaningful difference for customers and the donors they serve,” said Galvin. “I look …

Read more
  • 0

Haemonetics stock rises on Street-beating Q1, raised guidance

Haemonetics (NYSE:HAE) shares ticked up before hours on first-quarter results that topped the consensus forecast.

Shares of HAE were up 5.1% at $71 apiece before the market opened. They continued to rise and were up 7.8% at $72.84 in early-morning trading.

The Boston-based hematology device company posted profits of $19.9 million, or 38¢ per share, on sales of $261.5 million for the three months ended July 2, 2022, for a massive bottom-line gain out of the red on sales growth of 14.4%.

Adjusted to exclude one-time items, earnings per share were 58¢, 7¢ ahead of Wall Street, where analysts were looking for sales of $249 million.

“Positive first-quarter results across businesses affirm our long-range plan for transformational growth,” Haemonetics CEO Chris Simon said in a news release. Robust growth in plasma is evidence of improving momentum in plasma collections and hospital is an increasingly powerful driver of growth, with vascular closure…

Read more
  • 0

Haemonetics completes move to new Pennsylvania manufacturing facility

[Image from Haemonetics]Haemonetics (NYSE:HAE) announced today that it fully commenced operations at its new manufacturing center in Clinton, Pennsylvania.

Boston-based Haemonetics previously operated at a manufacturing plant in nearby Leetsdale, Pennsylvania, from 1990 until now.

According to a news release, the custom-built facility constitutes approximately 200,000 square feet in Clinton Commerce Park near Pittsburgh International Airport. Initial manufacturing began earlier this year at the site, with Haemonetics making use of both resources from the Leetsdale facility as well as new, advanced technology and manufacturing equipment to support demand for the production of disposables and consumables across its plasma and hospital businesses.

The Clinton facility also includes several environmentally-focused features, including smart controls on the HVAC systems, a recycled compressor heat system for more efficient temperature control and a closed loop pr…

Read more
  • 0

Haemonetics names James D’Arecca as chief financial officer

Haemonetics (NYSE:HAE) this week appointed James D’Arecca as chief financial officer, effective on April 11.

D’Arecca will oversee the company’s treasury, controllership and accounting, investor relations, tax, information technology and financial planning and analysis functions. He will report directly to president and CEO Chris Simon. He succeeds William Burke who will remain with Haemonetics in an advisory role through June 30.

“Haemonetics is recognized and respected for its long history of innovation and industry leadership in improving standards of care. I am excited to help the Company continue to achieve strong results, accelerate growth, and expand its impact throughout the world,” D’Arecca said in a news release.

Prior to joining the company, D’Arecca was the chief financial officer of TherapeuticsMD. He previously served as senior VP and chief accounting officer at Allergan and held leadership roles at Bausch + Lo…

Read more
  • 0

Haemonetics posts mixed-bag Q3, tightens guidance range

Haemonetics (NYSE:HAE) shares dipped slightly before hours on third-quarter results that were mixed compared to the consensus forecast.

The Boston-based company posted profits of $23.2 million, or 45¢ per share, on sales of $259.8 million for the three months ended Jan. 1, 2022, for a 27.1% bottom-line slide on sales growth of 8.1%.

Adjusted to exclude one-time items, earnings per share were 84¢, 11¢ ahead of Wall Street, where analysts were looking for sales of $266.7 million.

“Our third-quarter results reflect our agility and resilience in meeting the challenges of the pandemic on U.S. blood and plasma collections and some hospital products,” Haemonetics CEO Chris Simon said in a news release. “Plasma collections improved and we continued to convert customers to our latest NexSys and Persona technologies, while our hospital business delivered double-digit growth and a new record quarter for sales in hemostasis management and vascular closur…

Read more
  • 0